Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms UVA-AM-002
- 30 Oct 2018 Planned End Date changed from 1 May 2022 to 1 Oct 2023.
- 30 Oct 2018 Planned primary completion date changed from 1 May 2022 to 1 Oct 2023.
- 30 Oct 2018 Status changed from suspended to recruiting.